ME Therapeutics Holdings Inc.

METX

CA5527671054

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 10:48:40 2024-05-23 am EDT			5-day change	1st Jan Change
3.99 ^CAD	0.00%		-2.92%	+232.50%

Mar. 06	ME Therapeutics Holdings Inc. announced that it has received CAD 1.555 million in funding	CI
Feb. 27	ME Therapeutics Holdings Inc. announced that it expects to receive CAD 1.55 million in funding	CI

ME Therapeutics Holdings Inc. announced that it has received CAD 1.555 million in funding

March 05, 2024

On March 6, 2024, ME Therapeutics Holdings Inc. closed the transaction. No finder?s fees were paid in connection with the
offering.

Latest news about ME Therapeutics Holdings Inc.

ME Therapeutics Holdings Inc. announced that it has received CAD 1.555 million in funding	Mar. 05	CI
ME Therapeutics Holdings Inc. announced that it expects to receive CAD 1.55 million in funding	Feb. 26	CI
ME Therapeutics Holdings Inc. Provides Update on Current Research and Development Programs	Dec. 04	CI
ME Therapeutics Holdings Inc. Receives Funding Support for Preclinical Testing of Prodrug Candidates	23-10-23	CI

Chart ME Therapeutics Holdings Inc.

Duration

Period

More charts

ME Therapeutics Holdings Inc. is a Canada-based biotechnology company. The Company is involved in the discovery and development of novel immuno oncology therapeutics targeting immune suppression in cancer. The Companyâs lead candidate is a novel high affinity antibody drug that targets a key protein involved in the generation of suppressive myeloid cells. This antibody drug candidate is being developed to treat colorectal cancer. In addition, to its antibody drug candidate program, the Company is also developing a novel small molecule prodrug candidate designed to specifically target suppressive myeloid cells in the tumor environment. Its two development programs include its anti-G-CSF antibody and its myeloid target prodrug and are engaged in a discovery program to discover novel lipid nanoparticle formulations. Its anti-G-CSF antibody candidate (h1B11-12) is its advanced preclinical asset.

Sector

Biotechnology & Medical Research

Calendar

2024-06-02 - BIO International Convention

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ME THERAPEUTICS HOLDINGS INC.	+232.50%	69.03M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research